Ayala Pharmaceuticals Inc (ADXS)

[fbg0316]

O'Connor wasted a lot of money on what is now a construct that is becoming dated. Do you think a potential partner is essentially going to reimburse ADXS for O'Connor's incompetence? Unfortunately, we're the ones paying for it. Also, remember you had projected if I recall ADXS got around $25 million from Amgen for the first patient dosed in NEO. Well the quarterly report just released showed we got $0 for the first patient dosing. I'm still hopeful we'll get an AXAL partner, but I woulnd't be surprised if there was very little upfront, as it would be a benefit if they simply paid all remaining costs since it's no longer a focus to ADXS and low value compared to HOT and NEO.